The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
Open accessAbstract
Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti-angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoietin-2 (Ang-2) as a potential target in both naive and bevacizumab-treated glioblastoma. Ang-2 expression was absent in normal human brain endothelium, while the highest Ang-2 levels were observed in bevacizumab-treated GBM. In a murine GBM model, VEGF blockade resulted in endothelial upregulation of Ang-2, whereas the combined inhibition of VEGF and Ang-2 leads to extended survival, decreased vascular permeability, depletion of tumor-associated macrophages, improved pericyte coverage, and increased numbers of intratumoral T lymphocytes. CD206(+) (M2-like) macrophages were identified as potential novel targets following anti-angiogenic therapy. Our findings imply a novel role for endothelial cells in therapy resistance and identify endothelial cell/myeloid cell crosstalk mediated by Ang-2 as a potential resistance mechanism. Therefore, combining VEGF blockade with inhibition of Ang-2 may potentially overcome resistance to bevacizumab therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“Of note, based on expression profiling, GBMs have been subdivided in different genetic subtypes (Phillips et al, 2006; Verhaak et al, 2010), and a recent study suggests that only glioblastomas that display the proneural subtype are susceptible to bevacizumab therapy (Sandmann et al, 2015).”
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“In addition, and coinciding with the elimination of macrophages, blocking of Ang-2 led to “vessel normalization,” as evidenced by pruning of the chaotic vasculature, decreased vascular permeability and increased pericyte coverage (Jain, 2005).”
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 1×
“Although two phase III clinical trials reported prolonged progression-free survival in primary GBM, beneficial results appear to be transient as tumors eventually progress and the majority of patients does not benefit from an increased overall survival (Chinot et al, 2014; Gilbert et al, 2014).”
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 14×
“Interestingly, our observations are in line with recent findings suggesting that a subpopulation of TAMs, defined as CD206+/TIE2Hi/CXCR4Hi, accumulate around blood vessels after chemotherapy in breast cancer, where they promote tumor revascularization and relapse, partly by release of VEGF (Hughes et al, 2015).”
InfluentialVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 10×
“Following intracerebral implantation, GL261 tumor cells were allowed to establish for 5 days before anti-angiogenic therapy using AMG386 (Ang-1/Ang-2 peptibody; Amgen, Thousand Oaks, USA) (Oliner et al, 2004) and aflibercept (VEGF-trap) (SanofiAventis, Frankfurt, Germany) (Holash et al, 2002) was initiated.”
InfluentialHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Fiedler, U., Reiss, Y., Scharpfenecker, M., Grunow, V., Koidl, S., Thurston, G., Gale, N. W., Witzenrath, M., Rosseau, S., Suttorp, N., et al. (2006) · Nature Medicine · doi:10.1038/nm1351 · Cited by 933 · cited 1×
“Vice versa, Ang-2 deficiency impaired the recruitment of myeloid cells to sites of inflammation (Fiedler et al, 2006).”
Self-citationTumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · cited 3×
“…therapy in glioblastoma: targeting Ang-2 and VEGF signaling pathways Increased numbers of myeloid cells in cancer are associated with dismal prognosis (Biswas et al, 2013) and are implicated in mediating therapy resistance in preclinical models (Shojaei et al, 2007; Chung et al, 2013).”
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445 · cited 8×
“…bevacizumab therapy also affected the ratio of CD8/ CD3+ T lymphocytes that was highest in the S/RTx/CTx/Bev group (Fig 6I), suggesting that VEGF inhibition affects the intratumoral composition of T cells, as previously reported by others (Huang et al, 2012; Chung et al, 2013; Motz et al, 2014).”
InfluentialAngiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation
Scholz, A., Plate, K. H., & Reiss, Y. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12726 · Cited by 248
Self-citationCoffelt, S. B., Chen, Y.-Y., Muthana, M., Welford, A. F., Tal, A. O., Scholz, A., Plate, K. H., Reiss, Y., Murdoch, C., De Palma, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002802 · Cited by 220
Self-citationEffects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
Holopainen, T., Saharinen, P., D’Amico, G., Lampinen, A., Eklund, L., Sormunen, R., Anisimov, A., Zarkada, G., Lohela, M., Heloterä, H., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs009 · Cited by 216
Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., Herting, F., Yu, S., The, H. H., Martarello, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0081 · Cited by 201
Angiopoietin-2 promotes myeloid cell infiltration in a β2-integrin–dependent manner
Scholz, A., Lang, V., Henschler, R., Czabanka, M., Vajkoczy, P., Chavakis, E., Drynski, J., Harter, P. N., Mittelbronn, M., Dumont, D. J., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343293 · Cited by 102 · cited 11×
“By applying a transgenic mouse model with targeted expression of Ang-2 in the vasculature (Reiss et al, 2007), we observed infiltration of myeloid cells in multiple organs in a b2-integrin-dependent manner (Scholz et al, 2011).”
InfluentialSelf-citation
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Functional morphology of the blood–brain barrier in health and disease
Liebner, S., Dijkhuizen, R. M., Reiss, Y., Plate, K. H., Agalliu, D., & Constantin, G. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1815-1 · Cited by 872
Self-citationEmerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer
Kong, D.-H., Kim, Y., Kim, M., Jang, J., & Lee, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041057 · Cited by 683
Metadata
- Authors
- Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., Steinbach, J. P., Trojan, J., Glas, M., Herrlinger, U., Krex, D., Meinhardt, M., Weyerbrock, A., Timmer, M., Goldbrunner, R., Deckert, M., Braun, C., Schittenhelm, J., Frueh, J. T., Ullrich, E., Mittelbronn, M., Plate, K. H., & Reiss, Y.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-12-14
- Volume
- 8
- Issue
- 1
- Pages
- 39-57
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2261205543
- Cited by
- 169
- References
- 19
- FWCI
- 6.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.